Search
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalIt was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Eladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationalEladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare genetic disorder that ...
Asparagine
go.drugbank.com/drugs/DB00174ApprovedNutraceuticalWithdrawnA non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and M...
AGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's
Gemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalGemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemi...
Terconazole
go.drugbank.com/drugs/DB00251ApprovedIt is classified as a _triazole ketal derivative_.[A178096] Terconazole was initially approved by the FDA in 1987.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawn(From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].
Fitusiran
go.drugbank.com/drugs/DB15002ApprovedInvestigational[L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.
Cythioate
go.drugbank.com/drugs/DB11392ExperimentalVet approvedCythioate is a member of the organothiophosphate compounds that is used as an insecticide and anthelmintic. It is mainly used in veterinary as a treatment for fleas.